treatment decisions

  • March 7, 2023  

    Learnings from Pilot Study: Creating Treatment Templates to Serve More Glioblastoma Patients

    With: Adrienne Nugent, PhD

    A recent pilot study between Cancer Commons and the Musella Foundation for Brain Tumor Research & Information is identifying patterns that are being translated into treatment templates to better serve a larger group of GBM patients. Our Curious Dr. George asks Cancer Commons Scientist Adrienne Nugent, PhD, to discuss key factors that point to the best courses of action a patient might take, and about the clinical… Read more »

  • January 28, 2023  

    Using Live Cells from Patients to Find the Right Cancer Drug

    With: Clifford A. Reid, PhD

    Today, many cancer patients benefit from targeted drugs that are matched to the distinct genetic mutations found in their tumors. However, especially in late-stage cancer, this “precision oncology” strategy has not proven to be as transformative as people once hoped. Here, Curious Dr. George asks Clifford A. Reid, PhD, CEO of Travera, how his company is addressing this problem. Curious Dr. George: The U.S.… Read more »

  • January 17, 2023  

    How Would an Expert Manage His Own Advanced Hodgkin Lymphoma?

    With: Kevin Knopf, MD, MPH

    When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks oncologist Kevin Knopf, MD, how he would handle his own advanced Hodgkin lymphoma. Curious Dr. George: Please consider this hypothetical scenario—as a very busy practicing clinical oncologist during the COVID-19 pandemic, you were not paying much attention to… Read more »

  • December 23, 2022  

    10 Things I Learned in 10 Years at Cancer Commons That Could Save Your Life

    With: Marty Tenenbaum, PhD

    After facing his own cancer, Marty Tenenbaum, PhD, founded Cancer Commons to help others dealing with the disease. Here, Curious Dr. George asks him to share what he has learned. Curious Dr. George: As a well-known survivor of metastatic melanoma, and as the founder of Cancer Commons, you are often sought out by friends and acquaintances who have just been diagnosed with cancer or… Read more »

  • September 15, 2022  

    A New Champion for Cancer Caregivers

    With: Mike Looney, PhD

    Many people with advanced cancer can benefit from helpful caregivers, but family and friends who take on this role may have little background or training to do such a difficult job well. A new organization called Courage Groups aims to provide education and guidance in this collaborative journey. The founder is Mike Looney, PhD, a client and generous supporter of Cancer Commons, whose family… Read more »

  • June 8, 2022  

    Caregivers, You’re Not Alone: Webinar Highlights

    Sarah Stanley

    Ten years ago, Shelley Frisbie’s husband received a diagnosis of metastatic cancer and was told he had six months to live. Shelley and her husband immediately faced immense urgency and uncertainty. But with guidance from Cancer Commons founder Marty Tenenbaum, PhD, Shelley soon had a list of top resources, doctors, and medical institutions to consult for help with her husband’s case. “I now had… Read more »

  • October 1, 2018  

    What to Expect When Active Surveillance Leads to Prostatectomy Bookmark

    Emma Shtivelman, PhD

    Excerpt from MedPage Today:

    “A high proportion of men who entered active surveillance for early prostate cancer had one or more high-risk disease characteristics when they subsequently had radical prostatectomy, a Swedish study showed.

    “Medical records showed that 52 of 132 men had at least one adverse pathology feature at radical prostatectomy. All the men initially opted for active surveillance, and the median time from enrollment to surgery was 1.9 years.”

    Go to full article published by MedPage Today on Sep 21, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • September 25, 2018  

    Tool Predicts Risk for Late Breast Cancer Recurrence Bookmark

    Emma Shtivelman, PhD

    Excerpt from Healio:

    “An online prognostic tool accurately determined the risk for late distant recurrence among women with ER-positive breast cancer, according to a single-arm, prospective study.

    “The Clinical Treatment Score post-5 years (CTS5) tool could be used to determine whether patients should continue endocrine therapy 5 years after initial treatment.”

    Go to full article published by Healio on Sep 19, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.